Memo Therapeutics AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Memo Therapeutics to Present Phase II Results for First-in-Class BK Polyomavirus Treatment at World Transplant Congress
Memo Therapeutics will present interim Phase II results for potravitug, a monoclonal antibody targeting BK polyomavirus infection in kidney transplant recipients, at the World Transplant Congress in August 2025.
Memo Therapeutics AG Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for BK viremia in kidney transplant patients.
Memo Therapeutics Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for BK viremia in kidney transplant patients.
Memo Therapeutics AG Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has completed enrollment in its Phase II clinical trial of potravitug for treating BK viremia in kidney transplant patients.
Memo Therapeutics AG Completes Enrollment in Phase II Trial of Potravitug for BK Viremia
Memo Therapeutics AG has finished enrolling patients in its Phase II clinical trial of potravitug, a BKV-neutralizing antibody, for kidney transplant recipients.